Targeted Germline Sequencing Identifies Ultra-Rare DDR Variants in High-Risk Prostate Cancer

Authors

  • Rawaz Rizgar Hassan 1 Department of Biology, College of Science, Salahaddin University-Erbil, Kirkuk Road, 44001 Erbil, Kurdistan Region, Iraq
  • Abdulkarim Karim Department of Biology, College of Science, Salahaddin University-Erbil, Kirkuk Road, 44001 Erbil, Kurdistan Region, Iraq

Keywords:

Prostate cancer, sequencing, germ line mutation, DNA damage repair, Precision oncology

Abstract

Background: Prostate cancer (PCa) is a biologically heterogeneous disease, with a subset of cases driven by hereditary germline alterations. Methods: Targeted germline sequencing using the Twist Fixed Panel was performed in nine high-risk PCa patients (median age 47; range 30–61). Variants were classified based on ClinVar, gnomAD, and in silico prediction tools.

Results: Pathogenic and likely pathogenic variants in DNA damage repair (DDR) genes were identified, including BRCA2, BRIP1, PALB2, and BRCA1. A homozygous ATM variant was observed in one patient. Several ultra-rare variants in MLH3 and BARD1 were also detected. Most variants had allele frequencies <10-6. Conclusions: High-risk and early-onset PCa is associated with rare germline DDR alterations. These findings support expanded germline testing in younger patients and suggest potential relevance for precision oncology approaches, although functional validation is required..

References

Ionescu CA, Cozaru GC, Aşchie M, et al. Toward personalized surgery in advanced prostate cancer: stratification by PTEN, AR-V7, TP53, TMPRSS2-ERG, and ERBB2 genetic alterations. Chirurgia (Bucur). 2025;120(3):265-74.

https://doi.org/10.21614/chirurgia.3151

PMid:40637064

Gerhauser C, Favero F, Risch T, Rausch T, Stütz AM, et al. Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell. 2018;34(6):996-1011.e8.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-53.

https://doi.org/10.1056/NEJMoa1603144

PMid:27433846 PMCid:PMC4986616

Stopsack KH, Vijai J, Conry M, et al. Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer. Clin Cancer Res. 2025;31(1):122-9.

https://doi.org/10.1158/1078-0432.CCR-24-2483

PMid:39450704 PMCid:PMC12407385

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490-503.

https://doi.org/10.1200/JCO.18.00358

PMid:30625039

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74(2):218-25.

https://doi.org/10.1016/j.eururo.2018.01.035

PMid:29439820 PMCid:PMC6045965

Wu J, Wei Y, Pan J, Jin S, Dai L, Zheng X, et al. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients. Int J Cancer. 2021;148(3):673-81.

https://doi.org/10.1002/ijc.33324

PMid:33006389

Mitchell J, Camacho N, Shea P, et al. Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. Nat Commun. 2025;16(1):1779.

https://doi.org/10.1038/s41467-025-56944-1

PMid:39971927 PMCid:PMC11839991

Ivarsdottir EV, Gudmundsson J, Tragante V, et al. Gene-based burden tests of rare germline variants identify six cancer susceptibility genes. Nat Genet. 2024;56(11):2422-33.

https://doi.org/10.1038/s41588-024-01966-6

PMid:39472694

Stadler ZK, Maio A, Khurram A, et al. Redefining early-onset cancer and risk of hereditary cancer predisposition. J Clin Oncol. 2023;41(16 Suppl):10510.

https://doi.org/10.1200/JCO.2023.41.16_suppl.10510

Sayaman RW, Saad M, Thorsson V, et al. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54(2):367-86.e8.

https://doi.org/10.1016/j.immuni.2021.01.011

PMid:33567262 PMCid:PMC8414660

Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77(1):24-35.

https://doi.org/10.1016/j.eururo.2019.08.025

PMid:31495749 PMCid:PMC6926480

Taylor RA, Fraser M, Livingstone J, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. 2017;8:13671.

https://doi.org/10.1038/ncomms13671

PMid:28067867 PMCid:PMC5227331

Beebe-Dimmer JL, Zuhlke KA, Johnson AM, Liesman D, Cooney KA. Rare germline mutations in African American men diagnosed with early-onset prostate cancer. Prostate. 2018;78(5):321-6.

https://doi.org/10.1002/pros.23464

PMid:29356034 PMCid:PMC6912854

Ye Q, Ma B, Li L, et al. A peptide-based PROTAC degrader of BRCA2 sensitizes metastatic castration-resistant prostate cancer to PARP inhibition. Cancer Res. 2025;85(18):3490-502.

https://doi.org/10.1158/0008-5472.CAN-24-4096

PMid:40729484

Thooft ADJ, Joris S, Jacobs C, et al. Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review. Acta Oncol. 2025;64:1295-306.

https://doi.org/10.2340/1651-226X.2025.43374

PMid:40988318 PMCid:PMC12476058

Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, et al. Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study. Eur Urol Oncol. 2021;4(4):570-9.

https://doi.org/10.1016/j.euo.2020.12.001

PMid:33436325 PMCid:PMC8381233

Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71(5):740-7.

https://doi.org/10.1016/j.eururo.2016.11.033

PMid:27989354 PMCid:PMC5535082

Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, et al. Advanced prostate cancer with ATM loss: PARP and ATR inhibitors. Eur Urol. 2021;79(2):200-11.

https://doi.org/10.1016/j.eururo.2020.10.029

PMid:33176972

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76(6):831-42.

https://doi.org/10.1016/j.eururo.2019.08.019

PMid:31537406 PMCid:PMC6880781

Downloads

Published

2026-08-10

How to Cite

Rizgar Hassan, R., & Karim, A. (2026). Targeted Germline Sequencing Identifies Ultra-Rare DDR Variants in High-Risk Prostate Cancer. Galen Medical Journal, 15, e4248. Retrieved from https://journals.salviapub.com/index.php/gmj/article/view/4248

Issue

Vol. 15 (2026): 2026: In Progress

Section

Original Article

License

Copyright (c) 2026 Galen Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

https://creativecommons.org/licenses/by/4.0/